Overvågningsaktiviteterne efter godkendelsen voksede især for så vidt angik fabrikationsændringer i markedsføringstilladelserne og sikkerhedsrelaterede aktiviteter.
Activities relating to orphan medicinal products increased in 2002, including designation procedures, post-designation follow-up of orphan medicines, protocol and regulatory assistance, management of the special orphan medicines fund, policy support to the European Commission and relations with patient organisations.